Year: 2022

A scientific workshop will feature Dr. Rashmi Kanagal-Shamanna from the University of Texas MD Anderson Cancer Center delivering a presentation on the use of emerging technologies for prognostication and research into myeloid neoplasms Four scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research, including one poster covering a multi-site study in Spain on data analysis for OGM for leukemia and lymphoma research, will be presented at the conferenceSAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Society of Hematology (ASH) Annual Meeting and Exposition 2022 with a broad range of content covering optical genome mapping’s...

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share. All of the shares to be sold in the offering are to be sold by Prometheus. The gross proceeds to Prometheus from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. The offering is expected to close on or about December 13, 2022, subject to the satisfaction of customary closing conditions....

Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor of breast cancer risk than a standard-of-care risk assessment alone. The data was shared in a spotlight discussion at the 2022 San Antonio Breast Cancer Symposium. Working with industry-leading researchers, Myriad Genetics studied outcomes from more than 130,000 women who received RiskScore results. By analyzing data on whether women developed breast cancer after their initial test result, the study demonstrated that RiskScore was...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) (OTCQB:PGLDF) reports that it has closed the first tranche (the “First Tranche”) of its non-brokered private placement of units (the “Units”) of the Company, at $0.27/Unit, for gross proceeds of up to approximately $1 million (the “Offering”), previously announced on October 25 and November 25, 2022. The First Tranche consisted of 2,712,929 Units for gross proceeds of approximately $732,490. Each Unit consists of one common share in the capital of the Company (a “Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one additional non-flow-through common share in the capital...

TORONTO, Dec. 08, 2022 (GLOBE NEWSWIRE) — White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company“) is pleased to announce a non-brokered private placement of: (i) flow-through common shares at a price of $0.41 per share (each a “FT Share”); and (ii) common shares in the capital of the Company  at a price of $0.38 per common share (each a “Common Share”), for total gross proceeds of approximately $4,416,000 (the “Offering“). “We are very grateful for the continued support of our exciting and impactful exploration activities in the prolific and under explored White Gold District,” stated David D’Onofrio, Chief Executive Officer. Pursuant to an investor rights agreement between the Company and Agnico Eagle Mines Limited (TSX: AEM, NYSE: AEM) (“Agnico”) dated December 13, 2016, Agnico has indicated...

BOCA RATON, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) — Grom Social Enterprises, Inc. (NASDAQ: GROM) (the “Company”), today announced the pricing of a public offering of 1,415,682 units (the “Units”) at a price to the public of $2.89 per Unit and approximately 314,422 pre-funded units (the “Pre-Funded Units”) at a price to the public of $2.889 per Pre-Funded Unit. Each Unit consists of one share of common stock and two warrants, each to purchase one share of common stock. The warrants will have an exercise price of $2.89 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. Each Pre-Funded Unit consist of one pre-funded warrant and two warrants identical to the warrants in the Unit. The pre-funded warrant is exercisable for one share of common stock for $0.001 per share immediately...

Vancouver, BC, Dec. 08, 2022 (GLOBE NEWSWIRE) — WestKam Gold Corp. (TSX-V: WKG) (the “Company” or “WestKam”), reports that the Company has allowed the 8 claims which comprise the Bonaparte Project to revert back to the Crown. The Company is presently doing due diligence on several other projects, although there are no assurances that any of the other projects currently under review will meet management’s criteria for potential acquisitions or that they can be acquired on terms acceptable to the Company. The Company will provide shareholders with updates on the status of these opportunities if and when material information becomes available. ON BEHALF OF THE BOARD OF DIRECTORS “Peter Laipnieks”                         Peter Laipnieks, President & CEO        WestKam Gold Corp.Suite 900, 570 Granville StreetVancouver, BC V6C...

TORONTO, Dec. 08, 2022 (GLOBE NEWSWIRE) — Immutable Holdings Inc. (NEO: HOLD; OTC: IHDLF) (“Immutable Holdings” or the “Company”), a publicly-traded blockchain holding company, is pleased to announce NFT.com’s release of version 0.14 of its private beta. This marks the fourteenth release of the beta as NFT.com continues to make progress ahead of wider public general availability of the platform set to take place in 2023. The release brings a number of exciting new features to the platform including a new version of the Discover page. The page now offers greater insights and searchability for individual non-fungible tokens (“NFTs”), NFT.com profiles, and NFT collections. It also features a collection leaderboard, which highlights key data attributes about leading NFT collections including sales volumes and floor prices. This feature...

DUBLIN, Ireland, Dec. 08, 2022 (GLOBE NEWSWIRE) — Willis Towers Watson Public Limited Company (“WTW” or the “Company”) is pleased to announce that its Board has unanimously selected Stephen Chipman, former CEO of Grant Thornton U.S.; Jackie Hunt, former Chair of Allianz Asset Management and Allianz Life (U.S.); and Fredric Tomczyk, former President and CEO of TD Ameritrade, to join the Board, each with start dates effective April 1, 2023. The Board made these selections as part of its multi-year succession planning process, utilizing the assistance of a leading search firm. In addition, two current Directors – Brendan O’Neill and Linda Rabbitt – have given notice to WTW that they will not be standing for re-election at the Company’s next Annual General Meeting (“AGM”), to be held in the second quarter of 2023. Each has decided...